Arkolith/Insider Trading/EVLO/Form 4

Zung Jonathan B.

Chief Development OfficerEvelo Biosciences, Inc. (EVLO) · full profile →Form 4 · filed Oct 14, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 19, 2022Grant(A)115K—$0115K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001694665-22-000134) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML